Newron Pharmaceuticals S.p.A.
NWPHFOTCHealthcare
$20.00
+$0.00(+0.00%)
Market Cap$416115900
P/E Ratio—
52W High$20
52W Low$9.36
Newron Pharmaceuticals S.p.A. (NWPHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NWPHF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $51.39M | $9.06M | $6.09M | $5.76M | $5.26M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.29M |
| Gross Profit | $51.39M | $9.06M | $6.09M | $5.76M | $4.96M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 94.39% |
| Operating Expenses | |||||
| R&D Expenses | $13.64M | $13.15M | $12.05M | $10.76M | $16.33M |
| G&A Expenses | $7.38M | $3.98M | $3.54M | $3.49M | $8.06M |
| Total Operating Expenses | $25.22M | $20.69M | $19.68M | $17.78M | $22.70M |
| Operating Income | $26.17M | ($11.63M) | ($13.30M) | ($12.36M) | ($18.07M) |
| Operating Margin %(computed) | 50.93% | -128.40% | -218.28% | -214.46% | -343.59% |
| Interest Income | $0.14M | $0.18M | $0.06M | $2.86M | $2.18M |
| Interest Expense | $4.35M | $4.17M | $4.36M | $2.92M | $2.24M |
| Income Before Tax | $21.39M | ($16.20M) | ($17.47M) | ($14.88M) | ($19.62M) |
| Income Tax Expense | $5.55M | $0.02M | $0.02M | $0.02M | $1.38M |
| Net Income | $15.84M | ($16.22M) | ($17.49M) | ($14.90M) | ($21.00M) |
| Net Margin %(computed) | 30.83% | -179.13% | -287.05% | -258.61% | -399.35% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.85 | $-0.91 | $-0.98 | $-0.84 | $-1.18 |
| Wtd Avg Shares | 18.56M | 17.84M | 17.84M | 17.84M | 17.84M |
| EBITDA | $25.94M | ($11.83M) | ($13.32M) | ($11.76M) | ($17.16M) |
| EBITDA Margin %(computed) | 50.47% | -130.63% | -218.62% | -204.04% | -326.36% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · M
Explore more Newron Pharmaceuticals S.p.A. data
About Newron Pharmaceuticals S.p.A. (NWPHF) Income Statement
Newron Pharmaceuticals S.p.A. (NWPHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, NWPHF reported revenue of $0.05B, gross profit of $0.05B (gross margin 100.00%), and net income of $0.02B — a net profit margin of 30.83%.
Frequently asked questions
NWPHF · 4 questionsNewron Pharmaceuticals S.p.A. (NWPHF) reported revenue of $0.05B for 2024, up 467.4% year-over-year.
NWPHF revenueNWPHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09